LGND
NEUTRAL
$204.92
Live
Ligand Pharmaceuticals Incorporated · NASDAQ
Target $245.1
(+19.6%)
$98.89
52W Range
$227.92
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$4.09B
P/E
33.43
ROE
13.5%
Profit margin
46.4%
Debt/Equity
0.44
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
LGND presents a dichotomy between exceptional operational profitability and poor deterministic health/value scores. While the company boasts a massive 46.42% profit margin and strong revenue growth (39.4%), the Piotroski F-Score of 3/9 indicates weak financial trend momentum. The stock is trading at a significant premium to its Graham Number ($84.23) and Intrinsic Value ($42.91), suggesting the market is pricing in aggressive future growth. Bearish insider activity and a weak technical trend further temper the outlook despite strong analyst target prices.
Key Strengths
Exceptional profit margins (46.42%) and gross margins (64.29%)
Strong top-line growth with 39.40% YoY revenue increase
Extremely high liquidity indicated by a Current Ratio of 22.23
Low leverage with a Debt/Equity ratio of 0.44
Consistent history of earnings beats over the last 25 quarters
Key Risks
Severe overvaluation relative to Graham and Intrinsic value benchmarks
Weak financial health trend as evidenced by a Piotroski F-Score of 3/9
Bearish insider sentiment with 9 sell transactions and 0 buys
High Price/Sales ratio (15.24) making the stock vulnerable to growth decelerations
Strongly bearish technical trend (10/100)
AI Fair Value Estimate
Based on comprehensive analysis
$125.5
-38.8% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
45
Moderate
20
85
90
30
0
AI Verdict
Speculative Growth
Key drivers: High Profitability, Revenue Growth, Valuation Gap, Weak F-Score
Confidence
90%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E (20.70) is lower than trailing P/E
Watchpoints
- Price is ~2.4x the Graham Number
- Price is ~4.8x the Intrinsic Value
- High P/S ratio of 15.24
Future
85/100
Ref Growth rates
Positives
- Strong YoY revenue growth (39.4%)
- High analyst target price ($245.10)
- Strong operating margins
Watchpoints
- Recent Q/Q EPS decline of 31.4%
Past
90/100
Ref Historical trends
Positives
- Impressive 1Y return of +102.3%
- Long-term 5Y growth of +126.7%
- Consistent earnings surprise track record
Watchpoints
No urgent risks highlighted.
Health
30/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Very low Debt/Equity
- Massive current ratio
Watchpoints
- Piotroski F-Score of 3/9 indicates deteriorating fundamental trends
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$204.92
Analyst Target
$245.1
Upside/Downside
+19.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LGND and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LGND
Ligand Pharmaceuticals Incorporated
Primary
|
+126.7% | +173.3% | +102.3% | +15.3% | -7.4% | +2.7% |
|
ALHC
Alignment Healthcare, Inc.
Peer
|
+11.0% | +93.4% | +42.7% | +17.5% | -12.9% | -6.7% |
|
INDV
Indivior Pharmaceuticals, Inc.
Peer
|
+218.1% | +75.0% | +241.6% | +28.4% | -7.0% | +0.2% |
|
IRTC
iRhythm Holdings, Inc.
Peer
|
+43.4% | -13.2% | +16.6% | -34.6% | -3.7% | -1.3% |
|
AMRX
Amneal Pharmaceuticals, Inc.
Peer
|
+69.5% | +727.3% | +34.6% | +18.3% | -19.5% | -10.7% |
LGN
Ligand Pharmaceuticals Incorporated
Primary
5Y
+126.7%
3Y
+173.3%
1Y
+102.3%
6M
+15.3%
1M
-7.4%
1W
+2.7%
ALH
Alignment Healthcare, Inc.
Peer
5Y
+11.0%
3Y
+93.4%
1Y
+42.7%
6M
+17.5%
1M
-12.9%
1W
-6.7%
IND
Indivior Pharmaceuticals, Inc.
Peer
5Y
+218.1%
3Y
+75.0%
1Y
+241.6%
6M
+28.4%
1M
-7.0%
1W
+0.2%
IRT
iRhythm Holdings, Inc.
Peer
5Y
+43.4%
3Y
-13.2%
1Y
+16.6%
6M
-34.6%
1M
-3.7%
1W
-1.3%
AMR
Amneal Pharmaceuticals, Inc.
Peer
5Y
+69.5%
3Y
+727.3%
1Y
+34.6%
6M
+18.3%
1M
-19.5%
1W
-10.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
33.43
Forward P/E
20.7
PEG Ratio
N/A
P/B Ratio
3.98
P/S Ratio
15.24
EV/Revenue
14.19
EV/EBITDA
46.98
Market Cap
$4.09B
Profitability
Profit margins and return metrics
Profit Margin
46.42%
Operating Margin
33.59%
Gross Margin
64.29%
ROE
13.47%
ROA
2.36%
Growth
Revenue and earnings growth rates
Revenue Growth
+39.4%
Earnings Growth
N/A
Q/Q Revenue Growth
+39.37%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.44
Low debt
Current Ratio
22.23
Strong
Quick Ratio
21.83
Excellent
Cash/Share
$36.78
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
95.0%
Op. Margin
33.6%
Net Margin
75.1%
Total Assets
$1.6B
Liabilities
$0.5B
Equity
$1.0B
Debt/Equity
0.53x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
99%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-26
$2.12
+163.7% surprise
2025-11-06
$3.09
+60.5% surprise
2025-08-07
$0.24
-28.5% surprise
Healthcare Sector Comparison
Comparing LGND against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
P/E Ratio
33.43
This Stock
vs
87.11
Sector Avg
-61.6%
(Discount)
Return on Equity (ROE)
13.47%
This Stock
vs
-49.88%
Sector Avg
-127.0%
(Below Avg)
Profit Margin
46.42%
This Stock
vs
-9.43%
Sector Avg
-592.1%
(Weaker)
Debt to Equity
0.44
This Stock
vs
3.74
Sector Avg
-88.1%
(Less Debt)
Revenue Growth
39.4%
This Stock
vs
80.78%
Sector Avg
-51.2%
(Slower)
Current Ratio
22.23
This Stock
vs
3.72
Sector Avg
+497.5%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LGND
Ligand Pharmaceuticals Incorporated
|
NEUTRAL | $4.09B | 33.43 | 13.5% | 46.4% | $204.92 | |
|
ALHC
Alignment Healthcare, Inc.
|
BEARISH | $3.85B | - | -0.7% | -0.0% | $19.22 | Compare |
|
INDV
Indivior Pharmaceuticals, Inc.
|
NEUTRAL | $3.82B | 18.62 | -% | 16.9% | $30.54 | Compare |
|
IRTC
iRhythm Holdings, Inc.
|
NEUTRAL | $3.72B | - | -36.6% | -6.0% | $115.24 | Compare |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
BEARISH | $3.72B | 53.77 | -% | 2.4% | $11.83 | Compare |
LGND
Ligand...
NEUTRAL
Mkt Cap
$4.1B
P/E
33.4
ROE
13.5%
Price
$204.92
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | KOZARICH JOHN W. | Director | Sale | 467 | $94,440 |
| 2026-04-01 | REARDON ANDREW THOMAS | Officer | Sale | 5,000 | $1,006,224 |
| 2026-04-01 | REARDON ANDREW THOMAS | Officer | Option Exercise | 5,000 | $261,350 |
| 2026-03-23 | SABBA STEPHEN L. | Director | Sale | 1,000 | $207,873 |
| 2026-03-11 | ESPINOZA OCTAVIO | Chief Financial Officer | Sale | 3,057 | $687,825 |
| 2026-03-11 | ESPINOZA OCTAVIO | Chief Financial Officer | Option Exercise | 2,405 | $222,823 |
| 2026-03-06 | LAMATTINA JOHN L | Director | Sale | 2,161 | $433,842 |
| 2026-03-06 | LAMATTINA JOHN L | Director | Option Exercise | 2,161 | $246,678 |
| 2026-03-04 | REARDON ANDREW THOMAS | Officer | Sale | 5,000 | $1,031,770 |
| 2026-03-04 | REARDON ANDREW THOMAS | Officer | Option Exercise | 5,000 | $261,350 |
| 2026-03-04 | ESPINOZA OCTAVIO | Chief Financial Officer | Sale | 13,423 | $2,762,822 |
| 2026-03-04 | ESPINOZA OCTAVIO | Chief Financial Officer | Option Exercise | 2,073 | $131,609 |
| 2026-03-03 | SABBA STEPHEN L. | Director | Sale | 2,034 | $409,851 |
| 2026-03-03 | SABBA STEPHEN L. | Director | Option Exercise | 2,034 | $141,383 |
| 2026-03-02 | KOZARICH JOHN W. | Director | Sale | 467 | $93,632 |
KOZARICH JOHN W.
Director
2026-04-01
467 shares
·
$94,440
REARDON ANDREW THOMAS
Officer
2026-04-01
5,000 shares
·
$1,006,224
REARDON ANDREW THOMAS
Officer
2026-04-01
5,000 shares
·
$261,350
SABBA STEPHEN L.
Director
2026-03-23
1,000 shares
·
$207,873
ESPINOZA OCTAVIO
Chief Financial Officer
2026-03-11
3,057 shares
·
$687,825
ESPINOZA OCTAVIO
Chief Financial Officer
2026-03-11
2,405 shares
·
$222,823
LAMATTINA JOHN L
Director
2026-03-06
2,161 shares
·
$433,842
LAMATTINA JOHN L
Director
2026-03-06
2,161 shares
·
$246,678
REARDON ANDREW THOMAS
Officer
2026-03-04
5,000 shares
·
$1,031,770
REARDON ANDREW THOMAS
Officer
2026-03-04
5,000 shares
·
$261,350
ESPINOZA OCTAVIO
Chief Financial Officer
2026-03-04
13,423 shares
·
$2,762,822
ESPINOZA OCTAVIO
Chief Financial Officer
2026-03-04
2,073 shares
·
$131,609
SABBA STEPHEN L.
Director
2026-03-03
2,034 shares
·
$409,851
SABBA STEPHEN L.
Director
2026-03-03
2,034 shares
·
$141,383
KOZARICH JOHN W.
Director
2026-03-02
467 shares
·
$93,632
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
10 analysts
Citigroup
2026-03-24
Buy
Buy
B of A Securities
2026-03-11
Buy
Oppenheimer
2026-02-27
Outperform
Outperform
HC Wainwright & Co.
2026-02-24
Buy
Buy
RBC Capital
2025-12-10
Outperform
Outperform
Stifel
2025-12-10
Buy
Buy
Citigroup
2025-12-09
Buy
RBC Capital
2025-11-10
Outperform
Outperform
Benchmark
2025-11-07
Buy
Buy
Oppenheimer
2025-11-07
Outperform
Outperform
Past News Coverage
Recent headlines mentioning LGND from our newsroom.
Newest → oldest
No matching news yet.